^
Association details:
| Biomarker: | MET amplification + RB1 wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tepmetko (tepotinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
Published date:
11/10/2023
Excerpt:
Cohort B of the phase 2 VISION trial evaluates tepotinib, an oral MET inhibitor, in patients with advanced NSCLC with high-level METamp who were enrolled by liquid biopsy....In exploratory biomarker analyses, focal METamp, RB1 wild-type, MYC diploidy, low circulating tumor DNA (ctDNA) burden at baseline, and early molecular response are associated with better outcomes.
DOI:
10.1016/j.xcrm.2023.101280
Trial ID:
